The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyleWe evaluated the effect of nateglinide on the occurrence of three coprimary outcomes: the...